Oncology ESMO 2024 - Daejin Abidoye At ESMO 2024, AbbVie presented new data across their solid tumour pipeline, displaying the company’s potential as an emerging leader in solid tumours.
News FDA cites 'significant concerns' with ADC lymphoma trial ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
